Managed Healthcare Executive® State of the Industry Survey Results, Part 1
Respondents ranked labor shortages and closing healthcare disparities the highest when asked what about most important issues facing U.S. healthcare in 2023.
What issues and challenges in healthcare will loom the largest this year?
That was question we asked in our annual State of the Industry this year. Respondents rated issues on a scale of 1-10 with 10 being the most important. We then weighted the answers with 10 having a value of 10, 9 having a value of 9, and so on.
The results were close but labor shortages ranked the highest in importance (weighted score of 6.73), followed by closing healthcare disparities (6.69) and long covid (6.63).
Adoption of the biosimilars (6.37) and interoperability (6.27) came out at the bottom of the importance ranking.
It is not surprising that labor shortages topped the list. The news has been full of stories about staffing shortages and related labor unrest. The U.S. Bureau of Labor Statistics has projected that there will be 200,000 openings for registered nurses each year over the next eight years. The bureau says employment of nurses is expected to grow by 6% in the 2020s, but that is about the same rate of growth as other occupations. The openings are the result of retirements and people leaving nursing for other professions.
The MHE State of the Survey was conducted in late November and early December 2022. Our colleagues at Medical Economics® helped disseminate the survey. The survey had just over 450 respondents.
In this latest episode of Tuning In to the C-Suite podcast, Briana Contreras, an editor with MHE had the pleasure of meeting Loren McCaghy, director of consulting, health and consumer engagement and product insight at Accenture, to discuss the organization's latest report on U.S. consumers switching healthcare providers and insurance payers.
Listen
Mental Health Comorbidities Affect Uptravi Prescribing for PAH
October 23rd 2024New real-world data suggest that physicians are cautious about prescribing the prostacyclin-receptor agonist Uptravi (selexipag) to pulmonary arterial hypertension (PAH) patients with mental health conditions when evidence suggests that it is best to take a proactive approach to treating PAH.
Read More
In our latest "Meet the Board" podcast episode, Managed Healthcare Executive Editors caught up with editorial advisory board member, Eric Hunter, CEO of CareOregon, to discuss a number of topics, one including the merger that never closed with SCAN Health Plan due to local opposition from Oregonians.
Listen
High-Dose Eylea Shows Unique Properties in nAMD and DME | AAO 2024
October 22nd 2024A new statistical models shed light on why some patients can extend the dosing interval with Eylea (aflibercept) from 8 weeks to as long as 20 weeks for neovascular age-related macular degeneration (nAMD) or diabetic macular edema (DME).
Read More
